Living Well, Dying Well. A Research Programme to Support Living Until the End

Terminal Care Clinical Trial

— iLIVE  

Official title:

Living Well, Dying Well. A Research Programme to Support Living Until the End (iLIVE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04271085
• Other study ID #: H2020-825731
• Status: Completed
• Start date: September 1, 2020
• Est. completion date: July 31, 2023

Study information

• Verified date: September 2023
• Source: Erasmus Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. The primary outcome for the cohort study is a descriptive assessment of the concerns, expectations and preferences around dying and end-of-life care of patients and their relatives, in different settings and cultures..

Description:

Rationale: In the EU about 4 million people yearly die from a chronic illness. Many of these people die in pain or distress. Care for dying patients and their close relatives is often suboptimal. Objective: To contribute to high-quality personalized care at the end of life by: 1. Providing in-depth understanding of the concerns, expectations and preferences of patients in the last phase of life and their relatives 2. Understanding the cultural, gender, age, healthcare -related and socio-economic variance in these concerns expectations and preferences Study design: The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. Participants are requested to also involve a close relative. Both patients and relatives are asked to fill in a questionnaire, at baseline and after four weeks. If patients die during the study, the relative is asked to fill in a post-bereavement questionnaire. Medical files are studied to assess health care use in the last days of life. Main study endpoints: The primary outcome for the cohort study is a descriptive assessment of patients' concerns, expectations and preferences around dying and end-of-life care, at baseline and after one month of follow-up. Potential risks and benefits associated with participation: The study population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening or stigmatizing participants. If patients feel burdened by participating in the study, they are encouraged to indicate that. The investigators will develop a protocol for researchers and interviewers to address such situations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: July 31, 2023
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria patients:

• The patient is aware that recovering from his/her disease is unlikely, to be assessed by the attending physician
• The attending physician would not be surprised if the patient were to die within 6 months
• If the physician is uncertain about the surprise question, the patient is eligible if presenting with at least one SPICT indicator:

General SPICT indicators:

• Unplanned hospital admission
• Performance status is poor or deteriorating, with limited reversibility (eg stays in bed or in a chair for more than half the day)
• Depends on others for care due to increasing physical and/or mental health problems; person's carer needs more help and support
• Progressive weight loss; remains underweight; low muscle mass
• Persistent symptoms despite optimal treatment of underlying condition(s)
• Person (or family) asks for palliative care; chooses to reduce, stop or not have treatment; or wishes to focus on quality of life Disease-specific SPICT indicators:

Cancer:

• Functional ability deteriorating due to progressive cancer
• Too frail for cancer treatment or treatment is for symptom control

Neurological disease:

• Progressive deterioration in physical and/or cognitive function despite optimal therapy
• Speech problems with increasing difficulty communicating and/or progressive difficulty with swallowing
• Recurrent aspiration pneumonia; breathless or respiratory failure
• Persistent paralysis after stroke with significant loss of function and ongoing disability

Heart/vascular disease:

• Heart failure or extensive, untreatable coronary artery disease; with breathlessness or chest pain at rest or on minimal effort
• Severe, inoperable peripheral vascular disease

Respiratory disease:

• Severe, chronic lung disease; with breathlessness at rest or on minimal effort between exacerbations
• Persistent hypoxia needing long term oxygen therapy
• Has needed ventilation for respiratory failure or ventilation is contraindicated

Kidney disease:

• Stage 4 or 5 chronic kidney disease (eGFR < 30ml/min) with deteriorating health
• Kidney failure complicating other life limiting conditions or treatments
• Stopping or not starting dialysis

Liver disease:

• Cirrhosis with one or more complications in the past year: diuretic resistant ascites; hepatic encephalopathy; hepatorenal syndrome; bacterial peritonitis; or recurrent variceal bleeds
• Liver transplant is not possible

Dementia/ frailty:

• Unable to dress, walk or eat without help
• Eating and drinking less, difficulty with swallowing
• Urinary and faecal incontinence
• Not able to communicate by speaking; little social interaction
• Frequent falls; fractured femur
• Recurrent febrile episodes or infections, aspiration pneumonia Other conditions: o Deteriorating and at risk of dying with other conditions or complications that are not reversible; any treatment available will have a poor outcome

Exclusion Criteria patients:

• The patient is incapable of filling in a questionnaire in the country's main language or in English (patients may be supported by relatives when filling in the questionnaire)
• The patient is incapable of providing informed consent to participate in the study, to be assessed by the attending physician

Inclusion Criteria relatives:

• Family, friend or other close relative of the patient
• 18 years or older
• The relative is aware that it is unlikely that that patient will recover from his/her disease

Exclusion Criteria relatives:

• The relative is incapable of filling in a questionnaire in the country's main language or in English
• The relative is incapable of providing informed consent to participate in the study

Related Conditions & MeSH terms

• Terminal Care

Intervention

Other:
• Observational study
No intervention involved

Locations

Country	Name	City	State
Argentina	Pallium Latinoamérica	Buenos Aires
Germany	University Hospital Cologne	Cologne
Iceland	Landspitali National University Hospital of Iceland	Reykjavík
Netherlands	Agnes van der Heide	Rotterdam
New Zealand	Arohanui Hospice Service	Palmerston North
Norway	Haukeland University Hospital	Bergen
Slovenia	University Clinic for Respiratory and Allergic Diseases Golnik	Ljubljana
Spain	Centro de Cuidados Paliativos Cudeca	Málaga
Sweden	Skåne University Hospital	Lund
Switzerland	Bern University Hospital	Bern
United Kingdom	University of Liverpool	Liverpool

Sponsors (14)

Lead Sponsor	Collaborator
Erasmus Medical Center	Arohanui Hospice Service Trust, Cudeca Hospice Foundation, Helse-Bergen HF, Klinikum der Universität Köln, Landspitali University Hospital, Lund University, Medical University of Vienna, Pallium Latinoamérica N.G.O, St Vincent's Hospital Melbourne, The University Clinic of Pulmonary and Allergic Diseases Golnik, University of Bern, University of Humanistic Studies, University of Liverpool

Countries where clinical trial is conducted

Argentina,  Germany,  Iceland,  Netherlands,  New Zealand,  Norway,  Slovenia,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)	Self developed questions, adapted from the Serious Illness Conversation Guide and the AEOLI questionnaire.	Baseline
Primary	Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)	Self developed questions, which were inspired by the Serious Illness Conversation Guide and the AEOLI questionnaire.	One month of follow-up
Secondary	Edmonton Symptom Assessment Scale (range 0-10, with higher score meaning worse outcome)	Symptoms	At baseline and after one month of follow-up
Secondary	European Organisation for Research and Treatment of Cancer Quality of Life C15-Palliative Care questionnaire, quality of life item (range 1-7, with higher score indicating better outcome)	Quality of life	At baseline and after one month of follow-up
Secondary	EuroQol-5d questionnaire (range 1-5 per item, with higher score indicating worse outcome)	Quality of life	At baseline and after one month of follow-up
Secondary	ICECAP Supportive Care Measure (range 1-4 per item, with higher score indicating worse outcome)	Experience of support	At baseline and after one month of follow-up
Secondary	Use of medical interventions (hospitalisation, medication, surgery, other interventions)	Retrospective assessment for patients who die during follow-up of medical interventions in the last week of patients' life, using a self-developed checklist	One week
Secondary	Bereaved relatives' experiences	International Care of the dying questionnaire (descriptive), Hogan Grief Reaction Checklist (despair (13 items) and personal growth (12 items) scales, range 1-5 per item)	8-10 weeks post-bereavement